3Code of Frederation of Regulation. Current good manufacturing practice for blood and blood components. Washington : US Goveminent Printing Office, 1998-04 BioLife Plasma Services. About Biolife-Press kit [ OL]. http:// www. biolifeplasma. com/html/about _ biolife/BioLife _ PressKit.
4WHO. Twenty-eighth world health assembly. WHA28.72 Utilization and supply of human blood and blood products. Geneva : WHO, 1975-03-13-30 [ 2009-10-13 ] http: //www. who int/ bloodsafetg/en/WHA28.72.pdf.
5WHO. Twenty-eighth world health assembly. WHA28.72 Utilization and supply of human blood and blood products. Geneva : WHO, 1975-03-13-30 [ 2009-10-13 ] http: //www. who int/ bloodsafetg/en/WHA28.72, pdf.
6WHO. Requirements for the collection, processing and quality control of blood components and plasma derivatives (revised 1992)//WHO,technical report series No 840[ S/OL]. Geneva: WHO, 1994 [ 2009-10-14 ] http ://www. who. int/bloodproducts/ publications/WHO.TRS_840-A2. pdf.
7WHO. WHO expert committee on biological standardization. 52 nd Report [ S/OL]. [ 2009-10-13 ] http://whqlibdoc.who. int/ trs/WHO. TRS_924. pdf.
9Council of Europe, Guide to the preparation, use and quality assurance of blood components( 1995 ). Brussels :Council of Europe Publishing, 1995 : 113-139.
10Therapeutic Goods Administration. The Australian code of good manufacturing practice (GMP) for blood and blood products[ S/ OL]. 2000-08-24[ 2009-10-13 ] http ://www. tga. gov. au/manuf/ gmpbltic.pdf.
